Latest Breaking News On - பல்கலைக்கழகம் மருத்துவமனை ஹைடெல்பெர்க் - Page 11 : comparemela.com
Vitamin-D-Mangel kann für fast neun von zehn COVID-19-Todesfällen verantwortlich sein
openpr.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.de Daily Mail and Mail on Sunday newspapers.
Blutverdünner: Dosierungsfehler und Wechselwirkungen mit neuer App vermeiden
heilpraxisnet.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heilpraxisnet.de Daily Mail and Mail on Sunday newspapers.
Immunocore presents phase 3 data comparing tebentafusp with investigator s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
(2) PRESS RELEASE
Immunocore presents phase 3 data comparing tebentafusp with investigator s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma
First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor
(Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.
email article
A novel bispecific protein significantly improved overall survival (OS) in metastatic uveal melanoma as compared with investigator s choice of treatment, including checkpoint inhibitors, a randomized trial showed.
Patients treated with tebentafusp had a median OS of 21.7 months versus 16.0 months for the control group. The benefit was consistent across all prespecified subgroups.
Grade 3/4 treatment-related adverse events (TRAEs) occurred infrequently, including a 1% incidence of severe cytokine release syndrome (CRS), reported Jessica C. Hassel, MD, of University Hospital Heidelberg in Germany, at the American Association for Cancer Research (AACR) virtual meeting. Tebentafusp showed a highly significant and clinically meaningful improvement in overall survival as first-line treatment of metastatic uveal melanoma, she said. It is the first investigational therapy in a phase III trial to improve overall survival in metastatic uveal melanoma, and this overal